Natural Killer Cells

[Journal of Controlled Release] Scientists developed an in situ sustained-release hydrogel delivery system for combined chemo-immunotherapy of glioma by combined chemotherapy drug and immunoadjuvant through the resection cavity local delivery.

[OncoImmunology] Researchers characterized γδ T cell expansions from healthy adult donors and observe that highly potent natural killer lymphocytes expand with γδ T cells under zoledronate and IL-2 stimulation.

[Surface Oncology] Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced the first patient has been dosed by GlaxoSmithKline in the Phase I study of GSK4381562 in patients with solid tumors.

[Biomarker Research] Inactivation of BCL11B were performed by CRISPR/Cas9 in human T cells. Immunophenotypic and transcriptional profiles of sgBCL11B T cells were characterized by cytometer and transcriptomics, respectively.

[Communications Biology] Researchers reported the isolation of 3H4, a murine human leukocyte antigen E (HLA-E)-VL9-specific IgM antibody that enhanced killing of HLA-E-VL9-expressing cells by an NKG2A+ NK cell line.

[Science Advances] Using a reverse translational approach, investigators showed a central role of NK cells in the radiation-induced immune response involving a CXCL8/IL-8–dependent mechanism.